Meclizine

Introduction Overview

Generic Name

meclizine

Brand Name

Antivert, Bonine, Bonine Max, Dramamine Less Drowsy, Dramamine Nausea Long Lasting, Travel-Ease, Medivert, Dramamine II, D-Vert, Driminate II, Meclicot, Ru-Vert-M, Meni-D, VertiCalm

Dosage Form

oral tablet (12.5 mg; 25 mg; 50 mg), oral chewable tablet (25 mg; 50 mg)

Drug Class

Anticholinergic antiemetics

Pharmacokinetics

Absorption:
Meclizine is rapidly absorbed following oral administration, with onset of action typically within 1 to 2 hours. It achieves peak plasma concentrations in approximately 1 to 4 hours, depending on formulation and patient factors. The drug's bioavailability is influenced by gastrointestinal pH and motility but is generally considered high, allowing effective systemic exposure following oral dosing. Factors such as food intake may delay absorption but do not significantly affect overall bioavailability.

Distribution:
Once absorbed, meclizine demonstrates extensive distribution throughout the body tissues, crossing the blood-brain barrier effectively to exert its central nervous system activity. It is highly lipophilic, facilitating penetration into CNS tissues, which is critical for its antiemetic and antivertigo effects. Meclizine is extensively bound to plasma proteins, primarily albumin and alpha-1 acid glycoprotein, with binding percentages ranging from 70-95%. This high protein binding impacts both its pharmacodynamics and duration of action.

Metabolism:
Meclizine undergoes hepatic metabolism predominantly via oxidative pathways mediated by cytochrome P450 enzymes, including CYP2D6. Phase I metabolism transforms meclizine into inactive metabolites; Phase II conjugation may occur but is not extensively characterized. Hepatic impairment can significantly alter the metabolism and clearance of meclizine, necessitating caution or dose adjustment in patients with liver dysfunction. There is limited data on active metabolites, suggesting that the therapeutic effects are primarily due to the parent compound.

Elimination:
Meclizine is eliminated primarily via hepatic metabolism and subsequent renal excretion of metabolites. The elimination half-life ranges between 6 to 24 hours, with variability based on patient age, hepatic function, and individual metabolic capacity. A small fraction of the unchanged drug may be excreted in the urine. Enterohepatic recirculation appears minimal. Renal impairment has a limited effect on meclizine clearance, but combined hepatic and renal dysfunction can prolong elimination, increasing the risk of toxicity.

Dosage Forms

Available Dosage Forms:
Meclizine is available in several oral dosage forms, including:
- Oral Tablet: 12.5 mg, 25 mg, 50 mg
- Oral Chewable Tablet: 25 mg, 50 mg
These formulations facilitate patient compliance, allowing choice depending on preference and clinical context.

Dosages for Adults and Adolescents:
For motion sickness, adults and children aged 12 years and older typically take 25 to 50 mg orally 1 hour before travel, with maintenance dosing every 24 hours as needed. For vertigo, dosing in adults and adolescents aged 12 and above generally ranges from 25 to 100 mg per day, divided into several doses based on clinical response. Dosage adjustments should be individualized according to efficacy and tolerability.

Specific Patient Populations:
In pediatric patients older than 12 years, dosing mirrors adult regimens, but cautious titration may be warranted. Elderly patients might require lower initial doses due to increased sensitivity and slower metabolism. Patients with hepatic or renal impairment warrant close monitoring and possible dosage reduction due to altered metabolism and elimination. Use in children younger than 12 years is generally not recommended without specialist oversight due to insufficient safety data.

Mechanism Of Action

Meclizine primarily exerts its therapeutic effects through antagonism of histamine H1 receptors in the central nervous system. By blocking H1 receptors, meclizine inhibits the action of endogenous histamine at postsynaptic sites involved in the vomiting reflex and vestibular stimulation, thereby reducing nausea, vomiting, and vertigo symptoms. This antihistaminic action also contributes to its sedative properties.

Beyond H1 receptor blockade, meclizine possesses significant anticholinergic (antimuscarinic) properties. It inhibits muscarinic acetylcholine receptors, particularly within the vestibular apparatus and central pathways regulating balance and motion perception. This dual blockade of histaminergic and cholinergic pathways disrupts the transmission of signals that mediate motion sickness and vestibular disturbances, providing symptom relief.

At the cellular level, meclizine modulates neurotransmission in the vestibular nuclei and central vomiting center located in the medulla oblongata. By dampening excitatory neurotransmission via receptor antagonism, it decreases neuronal excitability responsible for vertigo and emesis. Meclizine’s lipophilicity enhances its CNS penetration, increasing efficacy in targeting central vestibular receptors.

Comparatively, meclizine’s mechanism is similar to other anticholinergic antiemetics such as scopolamine but tends to produce less sedation, making it preferable for some patients. Clinical studies have demonstrated its effectiveness in preventing motion sickness and treating vertigo, with a favorable side-effect profile relative to older antihistamines. Ongoing research is exploring its roles in modulating vestibular compensation and neuroprotective effects in inner ear disorders.

Pharmacological Actions

Antihistaminic activity via selective H1 receptor antagonism in the central nervous system.
Anticholinergic effects through muscarinic receptor antagonism, reducing vestibular sensitivity.
Sedative properties resulting from central nervous system histamine blockade.
Inhibition of vestibular stimulation and suppression of the neuronal pathways causing nausea and vomiting.
Reduction of motion sickness symptoms including dizziness, nausea, and vomiting.
Amelioration of vertigo symptoms arising from inner ear disorders.
Decreased excitability of vestibular nuclei and medullary vomiting centers.
High lipophilicity allowing effective blood-brain barrier penetration.
Minimal stimulation of peripheral histamine receptors, leading to fewer peripheral side effects.
Modulation of neurotransmitter systems involved in balance and coordination.
Impact on central emetic pathways distinct from dopamine or serotonin receptor antagonists.
Reduced gastrointestinal motility effects compared to other anticholinergics.
Prolongation of action due to extensive tissue binding and slow dissociation from receptors.
Lower incidence of extrapyramidal symptoms relative to phenothiazine antiemetics.
Favorable profile for use in motion sickness prophylaxis and vestibular dysfunction.

Therapeutic Or Clinical Uses

Prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness in adults and children aged 12 years and older.
Management of vertigo symptoms resulting from vestibular system diseases such as labyrinthitis and Ménière’s disease.
Adjunctive therapy in balance disorders related to inner ear dysfunction.
Prophylactic use prior to exposure to motion-inducing environments such as travel by sea, air, or land.
Symptomatic relief in patients experiencing dizziness due to vestibular disturbances.
Supportive treatment for postural imbalance caused by vestibular impairment.
Off-label use in certain cases of chemotherapy-induced nausea, under specialist supervision.
Reduction of symptoms related to vestibular neuritis and vestibulopathy.
Treatment for mild to moderate vertiginous episodes in outpatient settings.
Utilization in clinical scenarios requiring minimization of sedative antiemetics’ side effects.
Therapeutic option for patients intolerant to other anticholinergic antiemetics like scopolamine.
Control of motion sickness symptoms in both recreational and occupational settings.
Potential use in managing vestibular migraine associated vertigo, pending further research.
Part of multi-modal therapy for balance rehabilitation.
Management of travel sickness in both adult and adolescent populations.

Side Or Adverse Effects

Drowsiness and sedation, commonly reported and dose-related.
Dry mouth due to anticholinergic effects on salivary glands.
Headache, possibly related to central nervous system effects.
Nausea or vomiting, though less frequently than other antiemetics.
Fatigue and general feeling of tiredness.
Blurred vision resulting from anticholinergic-induced pupillary dilation.
Dry eyes and difficulty with accommodation due to muscarinic blockade.
Constipation caused by decreased gastrointestinal motility.
Urinary retention, particularly in patients with prostatic hypertrophy.
Confusion or cognitive impairment, especially in elderly or sensitive individuals.
Hypersensitivity reactions, including rash, urticaria, or angioedema, though rare.
Paradoxical excitation manifesting as restlessness or nervousness.
Potential for dizziness or increased vertigo at higher doses.
Rare occurrences of tachycardia and palpitations.
Risk of central nervous system depression when combined with other sedatives.

Precautions

Avoid use in patients allergic to meclizine or any component of the formulation.
Use cautiously in individuals with glaucoma due to risk of increased intraocular pressure from anticholinergic effects.
Monitor patients with asthma or other chronic respiratory conditions as anticholinergic effects can thicken respiratory secretions.
Exercise caution in patients with benign prostatic hyperplasia or urinary retention problems.
Adjust dosing or avoid use in patients with liver or kidney impairment due to altered drug metabolism and clearance.
Inform patients about potential sedation and advise against driving or operating heavy machinery until tolerance is established.
Avoid concurrent use with alcohol or central nervous system depressants to prevent additive sedation.
Pregnant or breastfeeding women should use meclizine only if clearly needed and advised by a healthcare provider.
Evaluate for possible drug interactions before initiation, especially with sedatives, anticonvulsants, and psychotropic agents.
Elderly patients should receive the lowest effective dose to minimize adverse cognitive or anticholinergic effects.
Instruct patients to chew chewable tablets thoroughly before swallowing to ensure correct dosing.
Do not use in children under 12 years of age without medical supervision due to insufficient safety data.
Monitor for signs of anticholinergic toxicity in susceptible populations.
Discontinue use and seek medical advice if allergic reactions or severe side effects occur.
Ensure adequate hydration to mitigate some anticholinergic side effects such as dry mouth and constipation.

Warnings

Do not use if allergic to meclizine or similar antihistamines due to risk of hypersensitivity reactions.
May impair mental alertness, coordination, and reaction times; avoid driving or hazardous activities until effects are known.
Increased sedation can occur when combined with alcohol, sedatives, narcotic pain medications, muscle relaxants, or medications for anxiety, depression, or seizures.
Use with caution in patients with glaucoma, enlarged prostate, asthma, or other respiratory diseases due to anticholinergic effects.
Potential to cause urinary retention in susceptible individuals; monitor urinary function carefully.
Avoid chronic or high-dose use without medical supervision due to risks of central nervous system effects and toxicity.
Pregnancy Category B: use only if benefit outweighs potential risk; limited human data available.
Breastfeeding mothers should consult healthcare providers as meclizine is excreted in breast milk in small amounts.
Elderly patients have increased sensitivity to anticholinergic side effects and CNS depression.
Risk of confusion or hallucinations in geriatric patients; monitor cognitive status.
Avoid abrupt cessation after prolonged use to prevent potential withdrawal symptoms.
Use lowest effective dose for shortest possible duration to minimize adverse effects.
Store medication at room temperature away from moisture and heat to maintain efficacy.
Report any signs of allergic reaction such as rash, swelling, or difficulty breathing immediately.
Be aware of additive effects with other anticholinergic drugs to avoid toxicity.

Contraindication

Known hypersensitivity to meclizine or any of its components.
Use in children under 12 years without medical supervision.
Patients with narrow-angle glaucoma due to risk of increased intraocular pressure.
Individuals with a history of urinary retention unless benefits clearly outweigh risks and under close supervision.
Patients with severe liver disease requiring close monitoring or dose adjustment.
Concurrent use with other potent central nervous system depressants without medical advice.
Patients with known sensitivity to other anticholinergic agents.
Severe uncontrolled respiratory conditions where anticholinergic effects would be detrimental.
Avoid use during pregnancy unless clearly needed and prescribed by a healthcare provider.
Patients with severe prostatic hypertrophy with obstructive uropathy.
Known intolerance to oral tablet or chewable tablet excipients.
History of seizure disorders without appropriate medical evaluation.
Contraindicated in patients with known pheochromocytoma due to increased cardiovascular risk.
Significant cardiac arrhythmias or conduction abnormalities where anticholinergic effects may exacerbate symptoms.
Known hypersensitivity to antihistamines of the piperazine class.

Drug Interactions

Additive central nervous system depression with alcohol, sedatives, hypnotics, narcotic analgesics, and muscle relaxants.
Enhanced sedative effect when administered concomitantly with benzodiazepines or barbiturates.
Potential increased anticholinergic toxicity when combined with other anticholinergic agents such as atropine, scopolamine, or tricyclic antidepressants.
Possible interference with the metabolism of CYP2D6 substrates due to modest inhibition by meclizine.
Reduced efficacy of cholinergic agents used for Alzheimer’s disease or myasthenia gravis.
Increased risk of urinary retention when combined with drugs that cause urinary hesitancy.
Potential interaction with monoamine oxidase inhibitors (MAOIs) leading to enhanced anticholinergic side effects.
Caution when used with antihypertensives due to potential for additive hypotension caused by sedation or anticholinergic effects.
Possible reduced effectiveness of medications that rely on CNS alertness, such as stimulants.
Interaction with QT-prolonging drugs is unlikely but should be monitored in predisposed patients.
Concurrent use with opioid analgesics may potentiate CNS and respiratory depression.
Over-the-counter cold, allergy, and sleep aids may increase overall anticholinergic burden when taken with meclizine.
Herbal supplements like valerian or kava may exacerbate sedative effects.
Combination with seizure medications needs careful monitoring due to sedation and pharmacokinetic alterations.
Potential interference with diagnostic tests relying on pupil responsiveness or CNS status.

Preparations Of The Drug

Oral tablets available in 12.5 mg, 25 mg, and 50 mg strengths for precise dosing.
Oral chewable tablets provided in 25 mg and 50 mg strengths, suitable for patients with swallowing difficulties.
Bulk pharmaceutical powder and capsule formulations are available but less commonly used.
Over-the-counter formulations branded under names such as Bonine and Dramamine Less Drowsy for motion sickness.
Prescription-only formulations marketed as Antivert and others for vertigo management.
Orally administered forms designed for rapid absorption and ease of administration.
Non-injectable formulations tailored for outpatient and travel-related use.
Packaging options include blister packs, bottles, and unit-dose cartons for patient convenience.
Some preparations may include inactive ingredients such as lactose, magnesium stearate, and microcrystalline cellulose.
Extended-release formulations are not commonly available; immediate-release is standard.
Variations in excipient composition to reduce bitterness in chewable tablets.
Manufacturing adheres to current good manufacturing practices ensuring purity and efficacy.
Formulations designed to maintain chemical stability at room temperature for prolonged shelf life.
Labeling includes clear instructions for timing related to travel or symptom onset.
Compounded formulations may be available in certain settings for individualized dosing.